[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatrics-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatrics-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100617780","a-nurse-led-multicomponent-interventional-protocol-to-improve-sleep-quality-in-paediatric-oncology-patients-100617780",false,"NCT07323069","A Nurse-led Multicomponent Interventional Protocol to Improve Sleep Quality in Paediatric Oncology Patients","The Dreamcatchers Programme - A Nurse-led Multicomponent Interventional Protocol to Improve Sleep Quality in Paediatric Oncology Patients: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Children who can read and communicate in Chinese\n* Aged 6 to 12 years old (school-aged children).\n* Diagnosed with cancer and currently undergoing active treatment.\n* Identified as experiencing sleep disturbances, defined by a Chinese Pittsburgh Sleep Quality Index (PSQI) global score of ≥5.\n\nExclusion Criteria:\n\n* Diagnosed with hematological diseases unrelated to cancer (e.g., sickle cell anemia, thalassemia).\n* Presence of severe cognitive impairment, which may hinder the ability to follow instructions or engage with intervention components.","ALL","6 Years","12 Years",{"count":20,"type":21},68,"ESTIMATED","INTERVENTIONAL",[24],"NA","Sleep is essential for a child's development, influencing cognitive function, emotional stability, recovery, and overall well-being. Prolonged and intensive treatments for pediatric oncology patients can lead to sleep disturbances that are often overlooked by caregivers and healthcare professionals as temporary side effects. Symptoms may include difficulty initiating or maintaining sleep, reduced sleep duration, or perceived poor sleep quality. Recent studies indicate that sleep disturbances affect between 13% to 50% of leukemia survivors and up to 80% of children with central nervous system tumors. A recent study in Hong Kong found that approximately 45% of pediatric oncology survivors continue to face sleep challenges, underscoring the global and local relevance of this issue.\n\nThese sleep disturbances in this vulnerable group often result from factors such as pain and nausea due to chemotherapy side effects, which can be exacerbated by corticosteroids. The immediate discomfort caused by sleep disruptions can significantly affect treatment adherence, daily activities, social interactions, and overall quality of life.\n\nWhile pharmacological approaches remain the standard treatment for pediatric sleep disturbances, this method carries significant risks, including potential drug interactions and dependence. Non-pharmacological options, however, empower patients and caregivers to manage sleep issues without increasing medication use, promoting a proactive approach to sleep health.\n\nIn response to the need to enhance sleep quality among pediatric oncology patients, the Dreamcatchers Programme was developed as a nurse-led initiative. This program focuses on relaxation and offers sustainable strategies for improved sleep through sleep hygiene practices, progressive muscle relaxation (PMR), and breathing exercises for both patients and caregivers. Evidence-based interventions equip nurses with holistic techniques that address gaps in their knowledge and skills.\n\nThis project proposal details a randomized controlled pilot study aimed at evaluating the feasibility and preliminary effectiveness of the Dreamcatchers Programme, setting the groundwork for a standardized sleep management protocol in pediatric oncology care.",[27],"Pediatrics Cancer",[29,30,31,32,33,34,35,36],"pediatrics","oncology","leukemia","solid tumour","sleep","sleep quality","quality of life","sleep disturbances","RECRUITING","2025-12-30",{"date":40,"type":41},"2026-01-07","ACTUAL",{"date":43,"type":41},"2025-09-15",{"date":45,"type":21},"2027-07",{"name":47,"class":48},"Chinese University of Hong Kong","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100254767","amh-as-a-predictor-of-infertility-risk-in-children-with-cancer-chance-100254767","NCT02595255","AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)","Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal\u002FPubertal Cancer Patients","CHANCE","Inclusion Criteria:\n\n* Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified from Wallace et al, 2005):\n\n  * High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation\n  * Moderate\u002FLow risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma.\n  * No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.\n\nExclusion Criteria:\n\n* CNS (central nervous system) irradiation, cerebral tumour\n* Current or previous ovarian disease\u002Fsurgery\n* Familial history of premature ovarian failure (no iatrogenic or surgical origins)\n* Previous known severe chronic disease potentially affecting normal growth or puberty (diseases inducing malnutrition, anorexia, genetic\u002Fcongenital disorders as Turner, Kallman, BPES(Blepharophimosis, ptosis, and epicanthus inversus syndrome) syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune diseases, cystic fibrosis, severe renal dysfunction)\n* Genetic\u002Fcongenital disorders inducing mental retardation","FEMALE","3 Years","14 Years",{"count":62,"type":21},275,"OBSERVATIONAL","While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk.\n\nThe primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.",[66,67,27,68],"Fertility Preservation","Lymphoma","Gonadotropin-releasing Hormone Agonist",[70],"chemotherapy\u002FGnRH (gonadotropin-releasing hormone) analogues\u002Flymphoma\u002Fchildren\u002Ffertility","2020-04-30",{"date":73,"type":41},"2020-05-04",{"date":75,"type":41},"2014-04",{"date":77,"type":21},"2036-12",{"name":79,"class":48},"Erasme University Hospital",10]